Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ZyVersa Therapeutics, Inc. - Common Stock (NQ: ZVSA )

1.140 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.140
Bid (Size) 1.110 (20)
Ask (Size) 1.130 (14)
Prev. Close 1.140
Today's Range 1.140 - 1.140
52wk Range 1.040 - 42.38
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial
From ZyVersa Therapeutics
Via GlobeNewswire
Life Sciences Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire

Performance

YTD
-87.05%
-87.05%
1 Month
-48.18%
-48.18%
3 Month
-62.25%
-62.25%
6 Month
-73.43%
-73.43%
1 Year
-96.03%
-96.03%

More News

Read More
ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update
From ZyVersa Therapeutics
Via GlobeNewswire
Life Sciences Investor Forum Agenda Announced for November 14th
From Virtual Investor Conferences
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
“Trump Media (NASDAQ: DJT) Surges on Election Day as SmallCap Stocks CRDL, ALBT, ZVSA, PRSO Emerge”
Via AB Newswire
Topics Government
Exposures Political
Dow Jumps 400 Points; Yum! Brands Posts Downbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
S&P 500 Gains 1%; Vimeo Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Nasdaq Gains Over 100 Points; US Trade Deficit Widens In September
Via Benzinga
ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes
From ZyVersa Therapeutics
Via GlobeNewswire
Why Palantir Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications
From ZyVersa Therapeutics
Via GlobeNewswire
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Via Benzinga
ZVSA Stock Earnings: ZyVersa Therapeutics Beats EPS for Q2 2024
Via InvestorPlace
ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model
From ZyVersa Therapeutics
Via GlobeNewswire
SmallCap Tech/Biotech Stocks July/Aug 2024: ZVSA, DYAI, ZVRA, PRSO, RLMD, VTAK, ENTO, INBS, KAVL
Via AB Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS